The Asia Pacific Head And Neck Cancer Therapeutics Market would witness market growth of 13.4% CAGR during the forecast period (2022-2028).
Head and neck cancers often develop in the squamous cells lining the head and neck's mucosal surfaces for example, those inside the mouth, throat, and voice box. These tumors are referred to as head and neck squamous cell carcinomas. In addition to squamous cell carcinomas, head and neck cancers can arise in the salivary glands, sinuses, muscles, or nerves of the head and neck, although these tumors are far less prevalent.
Head and neck cancer can form in the Oral cavity including the lips, the front two-thirds of the tongue, the gums, the lining of the cheeks and lips, the floor of the mouth under the tongue, the hard palate (bony top of the mouth), and the little patch of gum behind the wisdom teeth. The pharynx is a cylinder approximately 5 inches long that begins below the nose and connects to the esophagus.
In addition, the epiglottis is a little patch of tissue that covers the voice box to keep food from reaching the airways. The paranasal sinuses and nasal cavities are tiny cavities inside the skull bones around the nose and the nasal cavity is the cavity within the nose. The primary salivary glands are located near the jawbone on the surface of the mouth's floor. Salivary glands generate saliva. Small salivary glands are distributed throughout the mouth and throat's mucous membranes.
In the past 15 years, HNC risk factor trends have altered substantially. Due to a lack of awareness and the late discovery of cancer in its advanced stages, nearly half of all diagnosed cases are deemed fatal. HNC is the third most prevalent cancer in India, accounting for 52 067 fatalities and 77 000 cases in 2012. Many instances of HNC go untreated or unreported, the true incidence is substantially higher than the estimates. Numerous studies demonstrate that risk variables are not only etiological drivers of HNC but are also associated with an elevated prevalence risk of HNC. In addition to HPV, alcohol intake and cigarette use be the major risk factors for head and neck cancer (HNC).
The China market dominated the Asia Pacific Head & Neck Cancer Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $176.9 Million by 2028. The Japan market is estimated to grow a CAGR of 12.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 14.1% during (2022 - 2028).
Based on Therapy Type, the market is segmented into Immunotherapy, Chemotherapy, and Targeted Therapy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Head And Neck Cancer Therapeutics Market is Projected to reach USD 2.5 Billion by 2028, at a CAGR of 12.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
By Therapy Type
By Route of Administration
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 